Skip to main content
Premium Trial:

Request an Annual Quote

Celera Registers Shares with Nasdaq on Eve of Split with ABI

NEW YORK (GenomeWeb News) – Celera, which is scheduled to officially split tomorrow from parent firm Applera and sister company Applied Biosystems, has registered to have its shares float on the Nasdaq Stock Market.
 
The firm’s shares currently trade as a tracking stock of Applera on the New York Stock Exchange. Its stock will be delisted from the New York Stock Exchange when the split is finalized.
 
Celera had initially filed for the split in April. Under terms of the separation, shareholders of the Applera Group-Celera Group tracking stock will receive one share of new Celera Corporation shares for each share of the tracking stock they currently own. Upon completion of the deal, Celera will become an independent, publicly traded company.
 
 

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.